dulaglutide，度拉糖肽）2个额外的剂量（3.0mg，4.5mg），该药是一种胰高血糖素样肽-1（GLP-1）受体激动剂（RA），每周注射一次，用于治疗2型糖尿病。

对于 2 型糖尿病（T2D）血糖控制不佳的患者，提升 Dulaglutide（胰高血糖素样肽 - 1 受体激动剂，GLP - 1）剂量不如换用 Tirzepatide。研究发现，换用并加量 Tirzepatide 者 40 周后 21% 的人糖化血红蛋白 A1c（HbA1c）达标，且减重效果更好，安全性相似。此研究为 T2D 治疗 ...

为评估司美格鲁肽（Semaglutide）与度拉糖肽（Dulaglutide）治疗 2 型糖尿病的成本效益 ... 长期成本效益分析 基础案例分析结果：研究发现，与 1.5mg 度拉糖肽相比，0.5mg 和 1.0mg 的每周一次司美格鲁肽均能显著改善患者的健康结局。在 40 年的模拟中，0.5mg 司美格 ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of ...

For participants who were randomly assigned to receive the 1.5-mg dose, dulaglutide was initiated at the 0.75-mg dose for the first 4 weeks and then escalated to the 1.5-mg dose if the participant ...

The 40-week trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c ...

were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks.

Back to Healio SAN FRANCISCO — A 1.5 mg daily dose of dulaglutide may limit kidney function deterioration and the onset of end-stage renal disease for adults with type 2 diabetes and chronic ...